Samantha Semenkow, an analyst from Citi, has initiated a new Buy rating on Cullinan Management (CGEM).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Samantha Semenkow has given his Buy rating due to a combination of factors, primarily the strength and timing of Cullinan’s autoimmune pipeline. The lead program, CLN-978, targets CD19 with a T‑cell engager approach and is being tested in rheumatoid arthritis, systemic lupus erythematosus, and Sjogren’s disease, all sizable markets with significant unmet medical need and potential for blockbuster-level sales.
Looking ahead to 2026, Samantha highlights a dense schedule of clinical catalysts for CLN-978 across these indications that could reshape investor expectations if the data confirm a best-in-disease profile driven by robust and durable B‑cell depletion. She also notes that the current share price implies a low likelihood of success for this scenario, creating an appealing entry point, while the oncology portfolio, including CLN-049 in AML and U.S. economics from zipalertinib, offers additional upside and non-dilutive value optionality.
In another report released on February 1, Guggenheim also initiated coverage with a Buy rating on the stock with a $30.00 price target.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CGEM in relation to earlier this year.